Chinese Drug Firms Race To U.S. With Traditional Medicines
This article was originally published in PharmAsia News
Luye Pharma is the latest Chinese domestic drug manufacturer aiming to launch prescription traditional Chinese medicines in the U.S.
You may also be interested in...
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market
From requiring early notification to whole-process involvement, China is clearing a path for a far-reaching new biosecurity law, which if implemented will pose high hurdles for international firms planning to conduct clinical studies in the country, industry observers say.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.